Mingfeng Han

7.2k total citations · 4 hit papers
29 papers, 3.9k citations indexed

About

Mingfeng Han is a scholar working on Infectious Diseases, Neurology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mingfeng Han has authored 29 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 8 papers in Neurology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mingfeng Han's work include COVID-19 Clinical Research Studies (15 papers), SARS-CoV-2 and COVID-19 Research (14 papers) and Long-Term Effects of COVID-19 (8 papers). Mingfeng Han is often cited by papers focused on COVID-19 Clinical Research Studies (15 papers), SARS-CoV-2 and COVID-19 Research (14 papers) and Long-Term Effects of COVID-19 (8 papers). Mingfeng Han collaborates with scholars based in China, Germany and United States. Mingfeng Han's co-authors include Xiuyong Li, Wei Sun, Dongsheng Wang, Aijun Pan, Xiao‐Hua Zhang, Haiming Wei, Xiaohu Zheng, Yonggang Zhou, Tiantian Li and Xiaoling Xu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Molecules and Frontiers in Microbiology.

In The Last Decade

Mingfeng Han

26 papers receiving 3.8k citations

Hit Papers

Effective treatment of severe COVID-19 patients with toci... 2020 2026 2022 2024 2020 2020 2020 2020 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effective treatment of severe COVID-19 patients with tocilizumab
    2020 1.9k citations Xiaoling Xu, Mingfeng Han et al. Proceedings of the National Academy of Sciences profile →
  2. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19
    2020 742 citations Tuantuan Li, Mingfeng Han et al. profile →
  3. [Mental health survey of medical staff in a tertiary infectious disease hospital for COVID-19].
    2020 507 citations Jizheng Huang, Mingfeng Han et al. PubMed profile →
  4. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial
    2020 338 citations Ke Hu, Wei‐jie Guan et al. Phytomedicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mingfeng Han China 14 2.6k 1.5k 620 464 433 29 3.9k
Haojia Wang China 13 1.8k 0.7× 964 0.7× 395 0.6× 320 0.7× 677 1.6× 58 3.3k
Qinghong Guo China 15 1.8k 0.7× 962 0.7× 394 0.6× 319 0.7× 713 1.6× 55 3.4k
Ke Pu China 14 1.8k 0.7× 961 0.7× 394 0.6× 275 0.6× 666 1.5× 32 3.1k
Youqin Yan China 8 2.7k 1.1× 1.3k 0.9× 334 0.5× 324 0.7× 629 1.5× 12 3.6k
Emilie Sanchez United Kingdom 6 4.7k 1.8× 2.7k 1.8× 411 0.7× 863 1.9× 845 2.0× 8 6.8k
Fang Liu China 30 2.8k 1.1× 1.6k 1.1× 185 0.3× 594 1.3× 754 1.7× 156 5.4k
Jing Wan China 19 2.3k 0.9× 1.4k 1.0× 173 0.3× 469 1.0× 664 1.5× 45 4.0k
Xi Gou China 5 1.8k 0.7× 961 0.7× 394 0.6× 121 0.3× 628 1.5× 6 2.9k

Countries citing papers authored by Mingfeng Han

Since Specialization
Citations

This map shows the geographic impact of Mingfeng Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingfeng Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingfeng Han more than expected).

Fields of papers citing papers by Mingfeng Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingfeng Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingfeng Han. The network helps show where Mingfeng Han may publish in the future.

Co-authorship network of co-authors of Mingfeng Han

This figure shows the co-authorship network connecting the top 25 collaborators of Mingfeng Han. A scholar is included among the top collaborators of Mingfeng Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingfeng Han. Mingfeng Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jin, Mingji, Jin Piao, Mingfeng Han, et al.. (2025). Multi-trace elements-enriched functional drink accelerates gastric ulcer repair via the HGF/c-Met/STAT3 pathway. Journal of Functional Foods. 125. 106674–106674. 2 indexed citations
2.
Zhang, Xiaohua, et al.. (2025). Combined Inflammatory Markers for Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease With Respiratory Failure. Journal of Inflammation Research. Volume 18. 2513–2520. 1 indexed citations
3.
4.
Xu, Jing, Mingfeng Han, Ting Zhang, et al.. (2025). Longitudinal relationships between serum ferritin and prognosis among severe community-acquired pneumonia patients. Frontiers in Pharmacology. 16. 1556185–1556185.
5.
Han, Mingfeng, et al.. (2024). Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review. Frontiers in Medicine. 11. 1411279–1411279. 3 indexed citations
6.
Li, Yirong, et al.. (2024). Exploring the reform of pharmacology curriculum based on ChatGPT. Applied Mathematics and Nonlinear Sciences. 9(1). 1 indexed citations
7.
Shen, Ya, et al.. (2024). Drug-induced hypersensitivity syndrome related to piperacillin-tazobactam: a case report and review of the literature. Frontiers in Medicine. 11. 1338247–1338247. 3 indexed citations
8.
9.
Han, Mingfeng, et al.. (2024). Acute pneumonia due to Tropheryma whipplei diagnosed by metagenomic next-generation sequencing and pathology: A case report. Heliyon. 10(4). e26747–e26747. 2 indexed citations
10.
Wei, Yuanyuan, et al.. (2023). Differential Characteristics of Patients for Hospitalized Severe COVID-19 Infected by the Omicron Variants and Wild Type of SARS-CoV-2 in China. Journal of Inflammation Research. Volume 16. 3063–3078. 6 indexed citations
11.
Duan, Xiaoqiong, Yujia Li, Min Xu, et al.. (2023). Vaccination increased host antiviral gene expression and reduced COVID-19 severity during the Omicron variant outbreak in Fuyang City, China. International Immunopharmacology. 120. 110333–110333. 1 indexed citations
12.
Ren, Cuiping, Yong Gao, Cong Zhang, et al.. (2022). Respiratory Mucosal Immunity: Kinetics of Secretory Immunoglobulin A in Sputum and Throat Swabs From COVID-19 Patients and Vaccine Recipients. Frontiers in Microbiology. 13. 782421–782421. 13 indexed citations
13.
Xu, Xiaoling, Mingfeng Han, Tiantian Li, et al.. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 117(20). 10970–10975. 1874 indexed citations breakdown →
14.
Zheng, Xueying, Sihui Luo, Yong Sun, et al.. (2020). Asymptomatic patients and asymptomatic phases of Coronavirus Disease 2019 (COVID-19): a population-based surveillance study. National Science Review. 7(10). 1527–1539. 15 indexed citations
15.
Huang, Jizheng, et al.. (2020). [Mental health survey of medical staff in a tertiary infectious disease hospital for COVID-19].. PubMed. 38(3). 192–195. 507 indexed citations breakdown →
16.
Hu, Ke, Wei‐jie Guan, Ying Bi, et al.. (2020). Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine. 85. 153242–153242. 338 indexed citations breakdown →
17.
Han, Mingfeng, Mengyuan Xu, Yafei Zhang, et al.. (2020). Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity. Medical Microbiology and Immunology. 209(6). 657–668. 20 indexed citations
18.
Zhang, Yafei, Changtai Wang, Mingfeng Han, et al.. (2020). Discrimination of False Negative Results in RT-PCR Detection of SARS-CoV-2 RNAs in Clinical Specimens by Using an Internal Reference. Virologica Sinica. 35(6). 758–767. 25 indexed citations
19.
Wang, Ruirui, Min Pan, Xiumei Zhang, et al.. (2020). Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. International Journal of Infectious Diseases. 95. 421–428. 167 indexed citations
20.
Li, Shasha, Jinsong Li, Zhenhua Zhang, et al.. (2020). COVID-19 induced liver function abnormality associates with age. Aging. 12(14). 13895–13904. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haojia Wang Breakdown of academic impact, for papers by Qinghong Guo Breakdown of academic impact, for papers by Ke Pu Breakdown of academic impact, for papers by Youqin Yan Breakdown of academic impact, for papers by Emilie Sanchez Breakdown of academic impact, for papers by Fang Liu Breakdown of academic impact, for papers by Jing Wan Breakdown of academic impact, for papers by Xi Gou
Rankless by CCL
2026